Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 260

1.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14. Review.

2.

Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona.

Tan S, Ayutyanont N, Bhattarai B, Movahedi Z, Jayaram L, Gish R, Nadir A.

BMJ Open Gastroenterol. 2017 Sep 25;4(1):e000158. doi: 10.1136/bmjgast-2017-000158. eCollection 2017.

3.

Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network.

Liver Int. 2017 Sep 29. doi: 10.1111/liv.13604. [Epub ahead of print]

PMID:
28963781
4.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaan0241. doi: 10.1126/scitranslmed.aan0241.

PMID:
28954926
5.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2017 Sep 6. doi: 10.1002/hep.29509. [Epub ahead of print] No abstract available.

PMID:
28877549
6.

Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.

Zakalashvili M, Zarkua J, Weizenegger M, Bartel J, Raabe M, Zangurashvili L, Kankia N, Jashiashvili N, Lomidze M, Telia T, Kerashvili V, Zhamutashvili M, Abramishvili N, Hedskog C, Chodavarapu K, Brainard DM, McHutchison JG, Mo H, Svarovskaia E, Gish RG, Rtskhiladze I, Metreveli D.

Liver Int. 2017 Aug 7. doi: 10.1111/liv.13540. [Epub ahead of print]

PMID:
28782185
7.

Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase.

Wong RJ, Le A, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):146-148. doi: 10.1016/j.cgh.2017.07.012. Epub 2017 Jul 18. No abstract available.

PMID:
28733260
8.

Drugs in Development for Hepatitis B.

Dawood A, Abdul Basit S, Jayaraj M, Gish RG.

Drugs. 2017 Aug;77(12):1263-1280. doi: 10.1007/s40265-017-0769-2. Review.

9.

HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use.

Gish RG.

Gastroenterol Hepatol (N Y). 2017 May;13(5):292-295. No abstract available.

10.

Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.

Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG.

J Viral Hepat. 2017 Dec;24(12):1089-1097. doi: 10.1111/jvh.12736. Epub 2017 Jul 29.

PMID:
28581644
11.

Markov modeling in hepatitis B screening and linkage to care.

Sehr MA, Joshi KD, Fontanesi JM, Wong RJ, Bitmead RR, Gish RG.

Theor Biol Med Model. 2017 May 18;14(1):11. doi: 10.1186/s12976-017-0057-6.

12.

Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.

Abdul Basit S, Dawood A, Ryan J, Gish R.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):707-716. doi: 10.1080/17512433.2017.1323633. Epub 2017 May 17. Review.

PMID:
28460547
13.

Management of hepatitis C virus infection in the Asia-Pacific region: an update.

Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win KM, Yurdaydin C.

Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-1253(16)30080-2. Epub 2016 Dec 10. Review.

PMID:
28404015
14.

Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.

Block TM, Zhou T, Anbarasan N, Gish R.

Gastroenterol Hepatol (N Y). 2016 Nov;12(11):679-689.

15.

Future Therapy for Hepatitis B Virus: Role of Immunomodulators.

Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG.

Curr Hepatol Rep. 2016;15(4):237-244. Epub 2016 Nov 10. Review.

16.

Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease.

Kohli A, Alshati A, Georgie F, Manch R, Gish RG.

Therap Adv Gastroenterol. 2016 Nov;9(6):887-897. Epub 2016 Sep 14. Review.

17.

Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362. doi: 10.1002/cpdd.318. Epub 2016 Dec 12.

18.

Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.

Wong RJ, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG.

J Viral Hepat. 2017 Jan;24(1):17-21. doi: 10.1111/jvh.12609. Epub 2016 Sep 27.

PMID:
27677786
19.
20.

Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma?

Joshi K, Kohli A, Manch R, Gish R.

Clin Liver Dis. 2016 Aug;20(3):563-80. doi: 10.1016/j.cld.2016.02.012. Epub 2016 May 14. Review.

Supplemental Content

Loading ...
Support Center